Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

HBB rs334 , ABO R s8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Hyokyoung G Hong, Mateus H Gouveia, Martin Ogwang, Patrick Kerchan, Steven Reynolds, Constance N Tenge, Pamela A Were, Robert T Kuremu, Walter N Wekesa, Nestory Masalu, Esther Kawira, Tobias Kinyera, Xunde Wang, Jiefu Zhou, Isaac Otim, Ismail D Legason, Hadijah Nabalende, Herry Dhudha, Mediatrix Mumia, Francine G Baker, Temi Okusolubo, Leona W Ayers, Kishor Bhatia, James J Goedert, Joshua G Woo, Nathan Cole, Wen Luo, Belynda Hicks, Adebowale A Adeyemo, Ludmila Prokunina-Olsson, Daniel N. Shriner, Charles N Rotimi, George Chagaluka, W Thomas Johnston, Nora Mutalima, Eric Borgstein, George N Liomba, Steve Kamiza, Nyengo Mkandawire, Collins Mitambo, Collins Mitambo, Elizabeth Molyneux, Robert Newton, Michelle Manning, Joseph F Fraumeni, Jr., Ruth M Pfeiffer, Amy Hutchinson, Meredith Yeager, Swee Lay Thein, Stephen J. Chanock, Sam M. Mbulaiteye

Blood (2022) 140 (Supplement 1): 9314–9316.

https://doi.org/10.1182/blood-2022-170410

Published: 2022

Journal Articles

Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma

Blood (2022) 140 (Supplement 1): 9240–9241.

https://doi.org/10.1182/blood-2022-169500

Published: 2022

Journal Articles

Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Blood (2022) 140 (Supplement 1): 9233–9235.

https://doi.org/10.1182/blood-2022-169911

Published: 2022

Journal Articles

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Alireza Eghtedar, MD, Srdan Verstovsek, MD, PhD, Jorge E. Cortes, MD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Carol Bivins, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Solly George, RN, Robert Newton, PhD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2010) 116 (21): 509.

https://doi.org/10.1182/blood.V116.21.509.509

Published: 2010

Journal Articles

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Ruben A. Mesa, MD, FACP, Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Steven Friedman, MD, Robert Newton, Susan Erickson-Viitanen, Deborah Hunter, John Redman, MD, Swamy Yeleswaram, Edward Bradley, MD, Ayalew Tefferi, MD

Blood (2008) 112 (11): 1760.

https://doi.org/10.1182/blood.V112.11.1760.1760

Published: 2008

Journal Articles

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Jordan Fridman, PhD, Roberto Nussenzveig, PhD, Phillip Liu, PhD, James Rodgers, PhD, Timothy Burn, PhD, Patrick Haley, DVM, Peggy Scherle, PhD, Robert Newton, PhD, Gregory Hollis, PhD, Steven Friedman, MD, Srdan Verstovsek, MD, PhD, Kris Vaddi, PhD

Blood (2007) 110 (11): 3538.

https://doi.org/10.1182/blood.V110.11.3538.3538

Published: 2007

NARROW

HBB rs334 , ABO R s8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma

Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

HBB rs334 , ABO R s8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma

Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only